Alvotech (ALVO) FCF Margin (2022 - 2026)
Alvotech's (ALVO) quarterly FCF Margin came in at 14.76% in Q2 2026, down 5838.0% on a YoY basis from 0.26% in Q2 2025, and up 114.18% quarter-over-quarter from 104.12% in Q1 2026.
Powered by 
Analysis
Alvotech (ALVO) FCF Margin (2022 - 2026) Analysis & Trends
Alvotech (ALVO) has reported FCF Margin for 5 consecutive years, with 14.76% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, FCF Margin fell 5838.0% year-over-year to 14.76%; the trailing twelve-month figure through Jun 2026 stood at 39.62% (up 122.0% YoY), and the FY2025 full-year result was 5.17%, up 7215.0% from the prior year.
- FCF Margin climbed to 14.76% in Q2 2026 per ALVO's latest filing, from 104.12% in the prior quarter.
- Across five years, FCF Margin topped out at 76.29% in Q4 2025 and bottomed at 6981.41% in Q4 2022.
- Historically, FCF Margin has averaged 782.24% across 5 years, with a median of 191.02% in 2026.
- The sharpest annual moves came in 2023 and 2025: FCF Margin surged 550540 bps in 2023, then plunged 66345 bps in 2025.
- Over 5 years, FCF Margin stood at 6981.41% in 2022, then jumped by 79 bps to 1476.01% in 2023, then jumped by 81 bps to 277.92% in 2024, then soared by 127 bps to 76.29% in 2025, then sank by 81 bps to 14.76% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 14.76%, 104.12%, and 76.29% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.58 Bn | 38.93 Bn | 2.15 Bn | 7.41% |
| 2 | Viatris | 19.17 Bn | 18.28 Bn | 1.46 Bn | 8.76% |
| 3 | Dr Reddys Laboratories | 9.87 Bn | 9.70 Bn | 396.53 Mn | 3.10% |
| 4 | Amneal Pharmaceuticals | 5.48 Bn | 5.36 Bn | 334.51 Mn | -6.52% |
| 5 | Bausch Health Companies | 2.35 Bn | 507.63 Mn | 2.10 Bn | 20.79% |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn | 14.76% |
| 7 | Ani Pharmaceuticals | 1.48 Bn | 1.12 Bn | 165.89 Mn | 20.15% |
| 8 | Amphastar Pharmaceuticals | 995.96 Mn | 705.83 Mn | 93.47 Mn | 23.24% |
| 9 | Fennec Pharmaceuticals | 401.41 Mn | 360.16 Mn | 17.15 Mn | - |
| 10 | RedHill Biopharma | 176.59 Mn | 176.59 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 14.76% |
| Mar 31, 2026 | -104.12% |
| Dec 31, 2025 | 76.29% |
| Sep 30, 2025 | -756.55% |
| Jun 30, 2025 | 73.14% |
| Mar 31, 2025 | 32.51% |
| Dec 31, 2024 | -277.92% |
| Sep 30, 2024 | -93.10% |
| Jun 30, 2024 | -83.01% |
| Mar 31, 2024 | -573.89% |
| Dec 31, 2023 | -1,476.01% |
| Jun 30, 2023 | -446.71% |
| Dec 31, 2022 | -6,981.41% |
| Jun 30, 2022 | -355.43% |